| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to compounds of formula (Ia) or their pharmaceutically acceptable salts, tautomers, or N-oxides, for use in prevention or treatment of unhealthy conditions or diseases, mediated with cyclin-dependent kinase and glycogen synthase-kinase-3, such as cancerous diseases. In formula (Ia) X stands for group R 1 -A-NR 4 ; A stands for link, C=O, or NR g (C=O, where R 8 stands for hydrogen or C 1-3 alkyl; Y stands for link or alkylene chain, made of 1, 2 or 3 atoms of carbon; R 1 stands for carbocyclic or heterocyclic group, containing from 3 to 12 circular units; or saturated C 1-8 hydrocarbyl group, optionally substituted with one or more substituents selected from halogen (for instance, fluorine), hydroxygroups, C 1 . 4 alkoxygroups, and carbocyclic or heterocyclic groups, and where 1 or 2 atoms of hydrocarbyl group carbon may be optionally substituted with atom or group selected from O, S, NH, SO, SO 2 ; R 2 stands for hydrogen or methyl; R 3 is selected from hydrogen and carbocyclic or heterocyclic groups, containing from 3 to 6 circular units; and R 4 stands for hydrogen or methyl. Specified carbocyclic and heterocyclic groups are determined in formula of invention and may be optionally substituted with groups specified in invention formula. Objects of invention are also a pharmaceutical composition based on proposed compounds, their application to produce medicinal agents and methods of their application. n EFFECT: production of pharmaceutical composition based on proposed compounds for use in prevention or treatment of unhealthy conditions or diseases, mediated with cyclin-dependent kinase and glycogen synthase-kinase-3, such as cancerous diseases. n 48 cl, 6 tbl, 254 ex |